Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

(2022) L. Paz-Ares et al.   ANNALS OF ONCOLOGY

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

(2022) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

(2021) Tina Cascone et al.   NATURE MEDICINE

OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study

(2021) D. Carbone et al.   Journal of Thoracic Oncology

PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis

(2021) J. Lee et al.   Journal of Thoracic Oncology

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).

(2021) Heather A. Wakelee et al.   JOURNAL OF CLINICAL ONCOLOGY

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

(2021) Sacha I. Rothschild et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

(2020) Shugeng Gao et al.   Journal of Thoracic Oncology

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

(2020) Catherine A Shu et al.   LANCET ONCOLOGY

1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial

(2020) B. Besse et al.   ANNALS OF ONCOLOGY

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

(2020) Mariano Provencio et al.   LANCET ONCOLOGY

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

(2020) Joshua E Reuss et al.   Journal for ImmunoTherapy of Cancer

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

(2018) T R Cottrell et al.   ANNALS OF ONCOLOGY

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

(2016) J. Liu et al.   Cancer Discovery

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

(2015) M. Ilie et al.   ANNALS OF ONCOLOGY

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint

(2014) Matthew D Hellmann et al.   LANCET ONCOLOGY